[go: up one dir, main page]

MX2018002354A - Métodos para el tratamiento de una enfermedad poliquística renal. - Google Patents

Métodos para el tratamiento de una enfermedad poliquística renal.

Info

Publication number
MX2018002354A
MX2018002354A MX2018002354A MX2018002354A MX2018002354A MX 2018002354 A MX2018002354 A MX 2018002354A MX 2018002354 A MX2018002354 A MX 2018002354A MX 2018002354 A MX2018002354 A MX 2018002354A MX 2018002354 A MX2018002354 A MX 2018002354A
Authority
MX
Mexico
Prior art keywords
kidney disease
polycystic kidney
treatment
methods
modified oligonucleotides
Prior art date
Application number
MX2018002354A
Other languages
English (en)
Inventor
D Patel Vishal
Nelson Chau B
R Androsavich John
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of MX2018002354A publication Critical patent/MX2018002354A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente métodos para el tratamiento de una enfermedad poliquística renal, que incluye una enfermedad poliquística renal dominante autosómica, mediante el uso de oligonucleótidos modificados que se dirigen a miR-17.
MX2018002354A 2015-08-26 2016-08-25 Métodos para el tratamiento de una enfermedad poliquística renal. MX2018002354A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210031P 2015-08-26 2015-08-26
PCT/US2016/048603 WO2017035319A1 (en) 2015-08-26 2016-08-25 Methods for treatment of polycystic kidney disease

Publications (1)

Publication Number Publication Date
MX2018002354A true MX2018002354A (es) 2018-12-10

Family

ID=56855838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002354A MX2018002354A (es) 2015-08-26 2016-08-25 Métodos para el tratamiento de una enfermedad poliquística renal.

Country Status (14)

Country Link
US (3) US10633657B2 (es)
EP (2) EP3340993B1 (es)
JP (1) JP6929269B2 (es)
KR (2) KR20250049446A (es)
CN (2) CN108135922A (es)
AU (1) AU2016312590B2 (es)
CA (1) CA2995996A1 (es)
DK (1) DK3340993T5 (es)
ES (1) ES2954151T3 (es)
IL (1) IL257596B (es)
MA (1) MA44836A (es)
MX (1) MX2018002354A (es)
RU (1) RU2742300C2 (es)
WO (1) WO2017035319A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY202466A (en) * 2016-12-05 2024-04-30 Regulus Therapeutics Inc Methods for treatment of polycystic kidney disease
MX2019006332A (es) * 2016-12-05 2019-08-01 Regulus Therapeutics Inc Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.
EP3841220A1 (en) 2018-08-23 2021-06-30 Roche Innovation Center Copenhagen A/S Microrna-134 biomarker
WO2024026354A2 (en) * 2022-07-27 2024-02-01 The General Hospital Corporation Methods and compositions for use in treating autosomal recessive polycystic kidney disease (arpkd)
WO2024254639A1 (en) * 2023-06-16 2024-12-19 PYC Therapeutics Limited Compositions and methods for treatment of kidney disease
WO2025110217A1 (ja) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 嚢胞性腎疾患の予防及び／又は治療剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648914A4 (en) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
NZ586285A (en) 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
WO2007126150A1 (ja) * 2006-04-27 2007-11-08 National University Corporation Nagoya University 癌の新規治療用組成物
WO2008002971A2 (en) * 2006-06-29 2008-01-03 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2927045A1 (en) 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
US20090105174A1 (en) * 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
US8569381B2 (en) * 2008-05-23 2013-10-29 Targacept, Inc. Combination therapy for the management of hypertension
EP2925866B1 (en) * 2012-11-30 2018-07-25 Aarhus Universitet Circular rna for inhibition of microrna
JP2016534069A (ja) * 2013-10-24 2016-11-04 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｄａｃ６阻害剤での多嚢胞性疾患の治療
EP3105327A4 (en) * 2014-02-12 2017-10-18 Thomas Jefferson University Compositions and methods of using microrna inhibitors
MY202466A (en) 2016-12-05 2024-04-30 Regulus Therapeutics Inc Methods for treatment of polycystic kidney disease
MX2019006332A (es) 2016-12-05 2019-08-01 Regulus Therapeutics Inc Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.

Also Published As

Publication number Publication date
US20190153442A1 (en) 2019-05-23
DK3340993T5 (da) 2024-10-07
US11168325B2 (en) 2021-11-09
EP4268891A3 (en) 2024-01-24
AU2016312590B2 (en) 2021-12-02
US20220025372A1 (en) 2022-01-27
EP4268891A2 (en) 2023-11-01
CA2995996A1 (en) 2017-03-02
DK3340993T3 (da) 2023-08-21
KR20180080181A (ko) 2018-07-11
EP3340993B1 (en) 2023-06-14
RU2018108206A3 (es) 2020-01-14
IL257596A (en) 2018-04-30
CN108135922A (zh) 2018-06-08
NZ740040A (en) 2024-07-26
ES2954151T3 (es) 2023-11-20
AU2016312590A1 (en) 2018-03-15
JP6929269B2 (ja) 2021-09-01
KR20250049446A (ko) 2025-04-11
US10633657B2 (en) 2020-04-28
RU2742300C2 (ru) 2021-02-04
RU2018108206A (ru) 2019-09-27
WO2017035319A1 (en) 2017-03-02
WO2017035319A8 (en) 2021-03-11
US20200231971A1 (en) 2020-07-23
IL257596B (en) 2022-08-01
HK1256883A1 (en) 2019-10-04
EP3340993A1 (en) 2018-07-04
CN114404440A (zh) 2022-04-29
MA44836A (fr) 2018-07-04
JP2018528945A (ja) 2018-10-04

Similar Documents

Publication Publication Date Title
CO2019006234A2 (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal
PL3519420T3 (pl) Cykliczne związki dinukleotydowe
MX2018016331A (es) Formas cristalinas de compuesto de triazolopirimidina.
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2018003443A1 (es) Tratamientos para el cancer.
EA201691991A1 (ru) Мультиспецифические антитела
MX384883B (es) Métodos para usar activadores de piruvato cinasa.
MX2018002354A (es) Métodos para el tratamiento de una enfermedad poliquística renal.
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
BR112017022924A2 (pt) métodos para aperfeiçoamento hidráulico de culturas.
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
CL2015002084S1 (es) Accesorio para calzado.
BR112016029236A2 (pt) métodos para tratar prurido.
CL2019001526A1 (es) Métodos para el tratamiento de la enfermedad renal poliquística.
MX387903B (es) Proceso para la preparacion de acidos 3-hidroxipicolinicos.
CO2017010143A2 (es) Procesos para preparar fluorocetólidos
BR112017002139A2 (pt) ?método para preparar um composto?
CL2018000489A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
CO2017000543A2 (es) Lípido que comprende ácido docosapentaenoico
CL2016002256A1 (es) Un proceso mejorado para la preparación de exametazima
MX380241B (es) Proceso para preparar 3-cloro-2-vinilfenol.
ECSP19015143A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
UA114708U (uk) Тяговий привід електробуса